Skip to main content

Research Repository

Advanced Search

All Outputs (14)

Validation of a patient-reported outcome measure for giant cell arteritis (2023)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Bromhead, A., …Robson, J. C. (2024). Validation of a patient-reported outcome measure for giant cell arteritis. Rheumatology, 63(1), 181-189. https://doi.org/10.1093/rheumatology/kead201

OBJECTIVES: GCA is systemic vasculitis manifesting as cranial, ocular or large vessel vasculitis. A prior qualitative study developed 40 candidate items to assess the impact of GCA on health-related quality of life (HRQoL). This study aimed to determ... Read More about Validation of a patient-reported outcome measure for giant cell arteritis.

Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: International development of a glucocorticoid treatment-specific patient-reported outcome measure (2023)
Journal Article
Bridgewater, S., Shepherd, M. A., Dawson, J., Richards, P., Silverthorne, C., Ndosi, M., …Robson, J. C. (2023). Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: International development of a glucocorticoid treatment-specific patient-reported outcome measure. Rheumatology, 62(11), 3565–3575. https://doi.org/10.1093/rheumatology/kead081

OBJECTIVES: Glucocorticoids (GCs) ('steroids') are used to treat rheumatic diseases but adverse effects are common. We aimed to explore the impact of GC therapy on health-related quality of life (HRQoL), to inform the development of a treatment-speci... Read More about Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: International development of a glucocorticoid treatment-specific patient-reported outcome measure.

Assessing glucocorticoid toxicity: Are the measures sensitive enough? (2023)
Journal Article
Robson, J. C., Dawson, J., & Ndosi, M. (2023). Assessing glucocorticoid toxicity: Are the measures sensitive enough?. The Lancet Rheumatology, 5(3), e113-e114. https://doi.org/10.1016/S2665-9913%2823%2900037-1

The Glucocorticoid Toxicity Index (GTI) is a composite instrument designed to capture change in glucocorticoid-related morbidity over time.1 It was developed through consensus methods and multi- criteria decisions among 19 medical specialists, with... Read More about Assessing glucocorticoid toxicity: Are the measures sensitive enough?.

Health professionals' perspectives on psychological distress and meeting patients' support needs in rheumatology care settings: A qualitative study (2023)
Journal Article
Silverthorne, C., Daniels, J., Thompson, M., Robson, J. C., Ndosi, M., Swales, C., …Dures, E. (2023). Health professionals' perspectives on psychological distress and meeting patients' support needs in rheumatology care settings: A qualitative study. Musculoskeletal Care, 21(2), 537-544. https://doi.org/10.1002/msc.1730

Background: Patients with inflammatory rheumatic diseases (IRDs) face challenges including pain, fatigue and disease flares. Evidence suggests their levels of anxiety and depression are higher compared to the general population. Rheumatology teams re... Read More about Health professionals' perspectives on psychological distress and meeting patients' support needs in rheumatology care settings: A qualitative study.

ANCA associated vasculitis subtypes: Response (response to letter) (2022)
Journal Article
Austin, K., Janagan, S., Wells, M., Crawshaw, H., McAdoo, S., & Robson, J. C. (2022). ANCA associated vasculitis subtypes: Response (response to letter). Journal of Inflammation Research, 15, 5687-5688. https://doi.org/10.2147/JIR.S387397

Many thanks for the opportunity to respond to the interesting letter to the Editor from Merkel, Jayne, and Bekker, with regard to our publication “ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives”.1 In the management se... Read More about ANCA associated vasculitis subtypes: Response (response to letter).

Reply - October 2022 (2022)
Journal Article
Grayson, P. C., Ponte, C., Robson, J. C., Suppiah, R., Judge, A., Hutchings, A., …Merkel, P. A. (2022). Reply - October 2022. Arthritis and Rheumatology, 74(10), 1725-1726. https://doi.org/10.1002/art.42267

Drs. Yazici and Yazici question a specific aspect of the methodology used to develop and validate the 2022 ACR/EULAR classification criteria for ANCA-associated vasculitides. They state concerns with the fact that patients recruited into the Diagnost... Read More about Reply - October 2022.

Comment on: Benchmarking tocilizumab use for giant cell arteritis (2022)
Journal Article
Janagan, S., Guly, C., Skeoch, S., & Robson, J. C. (2022). Comment on: Benchmarking tocilizumab use for giant cell arteritis. Rheumatology Advances in Practice, 6(3), Article rkac069. https://doi.org/10.1093/rap/rkac069

It is with great interest we read the editorial on tocilizumab (TCZ) use in giant cell arteritis (GCA) published on 9th May, 2022 by Conway et al [1]. We write to share some of our data to add weight to the views expressed, particularly in relation t... Read More about Comment on: Benchmarking tocilizumab use for giant cell arteritis.

P301 Patient reported outcome measure for giant cell arteritis: Clinical testing (2022)
Journal Article
Almeida, C., Guly, C., Mackie, S., Bromhead, A., Stern, S., Dures, E., …Robson, J. C. (2022). P301 Patient reported outcome measure for giant cell arteritis: Clinical testing. Rheumatology, 61(Supplement_1), Article keac133.300. https://doi.org/10.1093/rheumatology/keac133.300

Background/Aims Giant cell arteritis (GCA) presents in people over 50, with headaches, visual involvement and large vessel vasculitis. A 30-item GCA-specific patient reported outcome measure (GCA PRO) was developed and tested in a clinical setting t... Read More about P301 Patient reported outcome measure for giant cell arteritis: Clinical testing.

P289 The effectiveness of interventions to reduce psychological distress in patients with autoimmune rheumatic conditions: A systematic review of effectiveness (2022)
Journal Article
Hulley-Mills, J., Silverthorne, C., Jones, B., Hooper, J., Robson, J., Dures, E., …Ndosi, M. (2022). P289 The effectiveness of interventions to reduce psychological distress in patients with autoimmune rheumatic conditions: A systematic review of effectiveness. Rheumatology, 61(Supplement_1), https://doi.org/10.1093/rheumatology/keac133.288

Background/Aims Autoimmune rheumatic conditions are multisystem chronic disorders associated with increased psychological distress. Consequences include poor medication adherence and high levels of disease activity. Psychological interventions may r... Read More about P289 The effectiveness of interventions to reduce psychological distress in patients with autoimmune rheumatic conditions: A systematic review of effectiveness.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis (2022)
Journal Article
Grayson, P. C., Ponte, C., Suppiah, R., Robson, J. C., Craven, A., Judge, A., …Merkel, P. A. (2022). 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 81(3), 309-314. https://doi.org/10.1136/annrheumdis-2021-221794

Objective To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in... Read More about 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis (2022)
Journal Article
Watts, R. A., Luqmani, R. A., Merkel, P. A., Hutchings, A., Judge, A., Khalid, S., …Suppiah, R. (2022). 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Annals of the Rheumatic Diseases, 81(3), 321-326. https://doi.org/10.1136/annrheumdis-2021-221796

OBJECTIVE: To develop and validate classification criteria for microscopic polyangiitis (MPA). METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identificatio... Read More about 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis.